In addition, it was demonstrated that ECH slows down the progression of MASLD by regulating mitochondrial function and inhibiting ferroptosis through the Nrf2/SLC7A11/GPX4 signaling pathway. The gene discussed is NFE2L2; the disease is metabolic dysfunction-associated steatotic liver disease.